Highlights
• Oxford Biomedica confirmed a Manufacturing and Supply Partnership with Aura Biosciences for its lead candidate.
• The partnership supports Aura's belzupacap sarotalocan through its Phase 3 programme and potential future commercial supply.
• OXB has already begun technical transfer ahead of process performance qualification and eventual commercial production work.
• Work spans development in Bedford, Massachusetts, and an FDA-approved commercial-scale Facility in Durham, North Carolina.
Two US sites, one late-stage candidate and a supply chain designed to run from Clinical Trials towards the market. Oxford Biomedica (LSE:OXB) has confirmed a manufacturing and supply partnership with Aura Biosciences, taking on production support for Aura's lead VDC candidate, belzupacap sarotalocan.
The scope of the partnership
The agreement covers manufacturing and supply for belzupacap sarotalocan through its Phase 3 programme. It also extends to potential future commercial supply, giving the relationship a reach that goes beyond the clinical stage should the candidate progress.
That two-part structure, clinical supply now and possible commercial supply later, sets the partnership up as a continuing relationship rather than a single production run.
Technical transfer under way
Oxford Biomedica (LSE:OXB) has already started the technical transfer process for Aura's candidate. The work is taking place ahead of two further milestones named in the announcement: process performance qualification, known as PPQ, and commercial production. Having the transfer under way positions OXB for those next stages of the programme.
Two sites, two roles
The partnership draws on two of OXB's US locations, each with a distinct function.
In Bedford, Massachusetts, Oxford Biomedica (LSE:OXB) is handling process and analytical development, the groundwork on how the product is made and tested. In Durham, North Carolina, the company operates an FDA-approved, commercial-scale viral vector facility, which provides the manufacturing capacity relevant to later-stage and commercial supply.
Pairing development expertise in one state with an approved commercial-scale facility in another gives Aura a route from process work through to larger-scale production within a single partner's network.
A confirmed relationship
The announcement carried the headline "OXB confirms partnership with Aura Biosciences", presenting the agreement as an established arrangement rather than a proposal under negotiation. It ties OXB to the candidate at the front of Aura's pipeline, from the current Phase 3 stage through to any future commercial supply.
What the announcement leaves open
Financial terms of the partnership were not included in the announcement. Timelines for the PPQ stage and for any commercial production were also not set out.
Understanding Technical Transfer and PPQ
Technical transfer is the process of moving a manufacturing method from one organisation to another so that the product can be made consistently at the new site. Process performance qualification, known as PPQ, is a later stage in which a manufacturing process is demonstrated at commercial scale to show that it performs as intended. The announcement names PPQ and commercial production as the two milestones that follow the transfer, which has already started. Together, these steps describe how a candidate moves from development towards supply.
Why the Two Sites Matter
The partnership uses two US locations with different roles. Bedford, Massachusetts handles process and analytical development, meaning the work on how the product is made and how its quality is tested. Durham, North Carolina houses an FDA-approved, commercial-scale viral vector facility, which provides the capacity relevant to later-stage and commercial supply. Viral vectors are modified viruses used to deliver genetic material in certain medicines, and manufacturing them requires specialist facilities and expertise. The agreement covers supply through the Phase 3 programme for belzupacap sarotalocan, Aura's lead VDC candidate, and extends to potential commercial supply, so it is designed to continue if the candidate progresses. The announcement did not include financial terms or timelines for the PPQ stage and any commercial production, so those details remain to be disclosed. Readers following Oxford Biomedica can look for later updates describing progress in technical transfer and the timing of the next milestones, since those will show how the relationship develops from the current Phase 3 stage towards the possible commercial stage described in the announcement.






Please wait processing your request...